US Pharm. 2009;34(5):36-38. 

Marlborough, Massachusetts-based Sepracor Inc. announced it has entered into a Settlement and License Agreement with Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc., to resolve the patent litigation against Barr involving Sepracor's Xopenex brand levalbuterol HCl Inhalation Solution products (1.25 mg/3 mL, 0.63 mg/3 mL, and 0.31 mg/3 mL) and to grant a license to Barr and Teva. The agreement permits the two companies to launch generic versions of these Xopenex Inhalation Solution dosages under terms of a nonexclusive license commencing on February 17, 2013.